AcornMed, a tumor precision medicine specialist based in Beijing, has reportedly raised RMB 200 million (USD 28.7 million) in a Series B financing round led by Yikai Venture Capital. Other investors included Lichen Investment, Qingdao Hongteng, and Wushi Capital. The proceeds will be used for research and development of tumor early screening products, product regulatory filings, and marketing and promotion.
Company Background and Achievements
Founded in 2018, AcornMed boasts a genome database of more than 100,000 cancer patients covering multiple cancers such as urinary system tumors, digestive system tumors, and blood tumors. The company has launched over 50 testing products and has established high-profile partnerships with Huawei, AstraZeneca, Roche Diagnostics, and others. These partnerships highlight AcornMed’s commitment to advancing precision medicine and improving patient outcomes through innovative diagnostic solutions.
Future Prospects and Strategic Use of Funds
The Series B financing round positions AcornMed to further enhance its capabilities in tumor early screening and precision medicine. By investing in R&D, regulatory filings, and marketing, AcornMed aims to solidify its position as a leader in the field, addressing significant unmet medical needs and contributing to the global fight against cancer.-Fineline Info & Tech
